Formoterol。一个更新的药理性质和管理哮喘的治疗效果。

文章的细节

引用

复制到剪贴板

巴托拉,Brogden RN

Formoterol。一个更新的药理性质和管理哮喘的治疗效果。

药。1998年2月,55(2):303 - 22所示。

PubMed ID

9506248 (在PubMed

]

文摘

Formoterol,选择性β2-adrenoceptor受体激动剂,产生有效的dose-proportional bronchodilation,持续时间长达12个小时,在可逆阻塞性呼吸道疾病患者。Bronchodilation是重要的在几分钟内吸入,在2小时内最大,在治疗剂量相当于由传统的标准剂量β2受体激动剂。在单剂的研究比较两种长效β2受体激动剂formoterol氟替卡松加沙美特罗,重大bronchodilation比氟替卡松加沙美特罗与formoterol更快实现。bronchodilation时间与药物相似。吸入的疗效formoterol已经等于或大于舒喘灵(沙丁胺醇),非诺特罗、特布他林在两个短期和长期的临床试验。Formoterol减少夜间哮喘的症状和减少需要救援药物而舒喘灵。最近的研究表明,增加吸入formoterol 12或24毫克每日两次现有吸入皮质类固醇疗法改善肺功能,减少与安慰剂比较,哮喘症状。在一个精心设计的研究中,严重的哮喘发作的频率在12个月内减少了formoterol添加到现有方案的吸入型皮质类固醇激素。宽容的支气管扩张剂反应formoterol尚未观察到长期的临床试验。因为长时间的行动,formoterol提供显著的治疗优势/ shorter-actingβ2受体激动剂治疗夜间和运动性哮喘。 Formoterol is effective in preventing exercise-induced asthma in adults and children and confers significantly more protection than salbutamol when administered 3 and 12 hours before exercise. In general, inhaled formoterol is well tolerated. The most commonly reported adverse effects, tremor and palpitations, are those traditionally associated with the use of beta 2-agonists. Oral formoterol and high doses of inhaled formoterol are associated with more adverse events than are the recommended doses of 6 to 24 micrograms. Formoterol is currently recommended for use as an alternative to increasing inhaled steroid dosage in patients whose symptoms are inadequately controlled despite therapy with low to moderate doses of inhaled steroids and intermittent short-acting beta 2-agonists, and results of recent studies support therapeutic guidelines. Long term clinical studies comparing formoterol and salmeterol have not yet been published. Further studies to evaluate the earlier use of formoterol in patients with mild to moderate asthma are needed to determine the role and long term safety of formoterol in the management of asthma.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Formoterol

药物靶点

药物	目标	类	生物	药理作用	行动
Formoterol	β2肾上腺素能受体	蛋白质	人类	是的	受体激动剂	细节